宫颈癌组织微小RNA联合检测对宫颈癌1年生存率的预测价值

doi:10.3969/j.issn.1671-7171.2022.01.025

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1184 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨宫颈癌组织微小RNA联合检测对宫颈癌1年生存率的预测价值。【方法】选取2017年4月至2019年4月在西北妇女儿童医院诊治的宫颈癌患者70例,所有患者均随访1年,统计患者1年生存率,根据生存情况分为死亡组(n=12)与存活组(n=58),比较两组患者年龄、国际妇产科联盟(FIGO)分期、分化程度、淋巴结转移情况、肿瘤大小,并于入院活检时留取标本检测微小RNA-21(miR-21)、miR-143和miR-373水平,采用多因素Logistic回归分析宫颈癌1年死亡的危险因素。【结果】死亡组年龄＞50岁、Ⅲ期和Ⅳ期、中分化和低分化、淋巴结有转移、肿瘤大小＞4 cm比例显著高于存活组,其差异有统计学意义(P<0.05);死亡组miR-21的Ct值显著低于存活组, miR-143的Ct值和miR-373的Ct值显著高于存活组,其差异均有统计学意义(P<0.05)。年龄＞50岁、Ⅲ/Ⅳ期、低分化、有淋巴结转移、肿瘤直径＞4 cm、miR-21＜20.10、miR-143＞26.23、miR-373＞34.55是宫颈癌患者1年死亡的危险因素(P<0.05)。【结论】微小RNA与宫颈癌预后相关,可联合患者其他临床情况,对宫颈癌1年生存率的评估提供依据。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王巧鸽
	田露

关键词 ：宫颈肿瘤/病理学, 微RNAs, 免疫组织化学, 存活率

Abstract：【Objective】To explore the value of combined detection of MicroRNA in cervical cancer tissues in predicting the 1-year survival rate of cervical cancer. 【Methods】A total of 70 patients with cervical cancer admitted to Northwest Women's and Children's hospital from April 2017 to April 2019 were selected for the study. All selected patients were followed up for one year. The 1-year survival rate of the patients was counted and divided into the death group (n=12) and the survival group (n=58). The age, FIGO stage, pathological grade, lymph node metastasis and tumor size of the two groups were compared. MicroRNA-21 (miR-21), microRNA-143 (miR-143) and microrna-373 (miR-373) were measured immediately after admission. Multivariate Logistic regression analysis was used to investigate the risk factors of cervical cancer death in 1-year survival. 【Results】The proportion of age>50 years old, FIGO Ⅲ and Ⅳ stage, moderately differentiated and poorly differentiated in pathological grade, lymph node metastasis and tumor size larger than 4 cm in the death group was significantly higher than that in survival group. The difference was statistically significant(P<0.05).The Ct value of miR-21 in the dead group was significantly lower than that in the survival group. The difference was statistically significant (P<0.05).The Ct values of miR-143 and miR-373 in the death group were significantly higher than those in the surviving group, and the difference were statistically significant (P<0.05).Age > 50 years, FIGO stage Ⅲ/Ⅳ, low differentiation, lymph node metastasis, tumor size >4 cm, miR-21＜20.10,miR-143＞26.23 and miR-373＞34.55 were risk factors for 1-year death in cervical cancer patients (P<0.05). 【Conclusion】MicroRNA is associated with the prognosis of cervical cancer, which can provide valuable reference,if combined with other clinical information of patients, for the evaluation of 1-year survival rate of cervical cancer.

Key words： Uterine Cervical Neoplasms/PA MicroRNAs Immunohistochemistry Survival Rate

收稿日期: 2021-12-03

中图分类号:

R737.33

通讯作者: *E-mail:sxwqg_1985@163.com

引用本文:

王巧鸽, 田露. 宫颈癌组织微小RNA联合检测对宫颈癌1年生存率的预测价值[J]. 医学临床研究, 2022, 39(1): 91-94.
WANG Qiao-ge, TIAN Lu. Value of Combined Detection of Tissue MicroRNA in Predicting 1-year Survival Rate of Cervical Cancer. JOURNAL OF CLINICAL RESEARCH, 2022, 39(1): 91-94.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2022.01.025 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2022/V39/I1/91

[1] WANG X, ZHANG J. Long noncoding RNA GAS5-ASI suppresses growth and metastasis of cervical cancer by increasing GAS5 stability[J].Am J Transl Res,2019, 11(8):4909-4921.
[2] 郭颖, 马冬, 贾世峰,等. 微小RNA-365和靶向E74样受体4在宫颈癌细胞的增殖及其临床意义[J].中国医学科学院学报, 2019, 41(2):220-227.
[3] 谭小浪,陈雯,汪砥.miR-125在宫颈癌组织中的表达及其临床意义[J].医学临床研究,2020,37(9):1363-1365.
[4] LUO H,XU R, CHEN B, et al. MicroRNA-940 inhibits glioma cells proliferation and cell cycle progression by targeting CKS1[J].Am J Transl Res,2019, 11(8):4851-4865.
[5] SOLOMON D, DAVEY D, KURMAN R,et al.The 2001 Bethesda System: terminology for reportingresult of cervical cytology[J].JAMA,2002, 287(16):2114-2119.
[6] 鲁琦, 张震宇. 国际妇产科联盟2018年版子宫颈癌分期标准的解读[J].中华妇产科杂志, 2019, 54(10):718-720.
[7] 申金莲, 余瑛, 申昌梅. 子宫颈原位癌的诊断及治疗[J].中国临床医生杂志, 2009, 37(4):17-18.
[8] CHEN C Z,LI L, LODISH H F,et al.MicroRNAs modulate hematopoietic lineage differeniation[J].Science,2004,303(5654):83-86.
[9] 杜秀銮, 戴欣, 赵海峰,等. 宫颈癌组织miR-769-5p,NUSAP1 mRNA表达变化及其临床意义[J].山东医药, 2020, 60(34):72-74.
[10] 段媛媛. 微小RNA-7在内分泌恶性肿瘤中的研究进展[J].医学研究生学报, 2018, 31(4):440-443.
[11] 何少仪, 孙小丽, 黎玉涵,等. 血清miR21在宫颈癌患者手术前后中的表达及临床意义[J].中华肿瘤防治杂志, 2018, 25(1):10-11.
[12] 张群珍, 欧宜学, 谢慧英. miR21,CK19及TSGF在宫颈癌患者血清中的表达及其临床意义[J].医学临床研究, 2018, 35(8):1502-1504.
[13] 刘文博, 陈玲玲, 曹丽娟. miR-21靶向PDCD4调控HPV16⁺及HPV18⁺宫颈癌细胞增殖的实验研究[J].病毒学报, 2020, 36(6):133-138.
[14] 吴盈盈, 王微, 孙峥嵘. 人乳头瘤病毒DNA甲基化与宫颈病变程度的关系[J].现代肿瘤医学, 2018, 26(17):149-152.
[15] 詹得文, 胡文龙, 殷嫦嫦. miR-143与骨肉瘤的研究进展[J].广东医学, 2019, 40(8):160-163.
[16] 陈燕, 袁马驰, 陈鑫,等. LncRNA SATB2-AS1调控miR-373-5p/BTG3轴对宫颈癌细胞增殖和凋亡的影响[J].中华内分泌外科杂志, 2021, 15(4):428-432.